A phase Ib/II, multicenter, open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma
A study for patients with mutant melanoma using study drugs LEE011 in combination with MEK162
Sponsor: Novartis Pharmaceuticals Corporation
Enrolling: Male and Female Patients
IRB Number: AAAN6610
U.S. Govt. ID: NCT01781572
Contact: Palak Thaker: 212-305-2055 / pt2433@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if the drugs LEE011 and MEK162, administered in combination, are safe and effective in treating people who have melanoma. Specifically, this study will evaluate the effects of the combination of the two drugs, LEE011 and MEK162, in melanoma, carrying specific mutation in a gene called NRAS. The changes in the NRAS gene may lead to cancer growth.
This study is closed
Investigator
Gary Schwartz, MD
Do You Qualify?
Do you have a confirmed diagnosis of locally advanced or metastic NRAS mutant melanoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Palak Thaker
pt2433@cumc.columbia.edu
212-305-2055
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE